炎症性肠病患者新冠疫苗接种率高但存在不公平性
新冠疫苗推荐用于所有炎症性肠病(IBD)患者。IBD患者疫苗接率历史上低于一般人群,但近期调查显示IBD人群新冠疫苗接种意愿高于一般人群;该调查96%为白人、88%拥有学士及以上学位,可能不代表整体IBD人群。既往研究已发现IBD人群流感疫苗接种存在差异。
要点
- 新冠疫苗推荐用于所有炎症性肠病患者。
- IBD患者疫苗接率历史上低于一般人群。
- 近期调查中IBD人群新冠疫苗接种意愿高于一般人群,但96%为白人、88%有学士及以上学位。
核心结论
- IBD患者新冠疫苗接种率高但存在不公平性,近期调查的接种意愿高于一般人群但样本代表性有限。
研究设计与样本
- 本文为针对IBD患者新冠疫苗接种情况的评论性文章,引用近期调查及既往研究进行讨论。
主要发现
- IBD患者疫苗接率历史上低于一般人群。
- 近期调查显示IBD人群新冠疫苗接种意愿高于一般人群。
- 该调查中96%的患者为白人,88%拥有学士及以上学位。
- 既往研究已发现IBD人群流感疫苗接种存在差异。
局限性
- 近期调查中96%的患者为白人,88%拥有学士及以上学位,可能不代表整体IBD人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Coronavirus disease 2019 (COVID-19) vaccines are recommended for all patients with inflammatory bowel disease (IBD).1 Patients with IBD historically have had low vaccine uptake relative to the general population.2 However, a recent survey suggested a rate higher than that of the general population with regard to COVID-19 vaccine intent among the IBD population. Their study was limited being that 96% of the patients surveyed identified as White, and 88% had attained a bachelor's degree or higher level of education.3 Therefore, these findings may not be representative of the IBD population as a whole. Previous studies have indeed identified disparities in influenza vaccine uptake within the IBD population.4,5.
引用
- Schell TL, Richard LJ, Tippins K, et al. High But Inequitable COVID-19 Vaccine Uptake Among Patients with Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2021. PMID: 34896281. doi:10.1016/j.cgh.2021.12.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。